Latest news with #AvantTechnologies
Globe and Mail
11 hours ago
- Business
- Globe and Mail
The Smart Money Is Moving Toward AI Healthcare Tools That Actually Touch Patients
Issued on behalf of Avant Technologies Inc. VANCOUVER – News Commentary – AI is rapidly infiltrating every corner of the healthcare system, but so far, ambient scribes have taken the lead as the most visible breakthrough. As adoption broadens, experts are now evaluating which tools offer real ROI—and how quickly early adopters could benefit. Clinician workloads are already shrinking thanks to voice AI, while hospitals are deploying intelligent agents to streamline operations and boost care quality. For investors still hunting early-stage opportunities in this space, several publicly traded names are showing fresh momentum, including Avant Technologies, Inc. (OTCQB: AVAI), NVIDIA Corporation (NASDAQ: NVDA), Novo Nordisk A/S (NYSE: NVO), Alphabet, Inc. (NASDAQ: GOOG, GOOGL), and Microsoft Corporation (NASDAQ: MSFT). Private-market momentum is heating up fast, with venture capital pouring into AI-driven healthcare startups. In the first quarter alone, AI companies secured over half of all digital health funding—underscoring the sector's growing appeal. Notable rounds include $45 million for Ellipsis Health and $28 million for Autonomize AI, both focused on reshaping clinical decision-making. From early diagnostics to advanced drug discovery, the pace of innovation is picking up—and retail investors are starting to take notice. One example is the rollout of AI-powered screenings for diabetic retinopathy now underway across Costa Rica, Nicaragua, and Panama. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. The fast, non-invasive test detects early retinal changes—often before symptoms appear—and delivers secure results within minutes. By embedding the service in retail pharmacies and preparing for a parallel launch in Mexico, the partners are bringing care closer to patients while generating real-world data to support broader commercialization. "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient." The rollout also gives Avant a timely proof point as it moves to consolidate Vision AI under one roof. Earlier this month, the company signed a non-binding letter of intent to acquire 100% of Ainnova Tech —bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Management sees the unified cap table as a potential draw for both investors and strategic partners. While the legal teams work through due diligence, engineers are finalizing a low-cost, automated retinal camera built to work seamlessly with the Vision AI platform. Legacy fundus cameras can run into the tens of thousands and typically require skilled operators. Avant's prototype is fully automated, cloud-connected, and designed for a fraction of the cost. If performance holds up to internal testing, the system could enable large-scale diabetic screenings in clinics and low-resource settings—without the need for additional specialist staff. Vision AI is also expanding beyond diabetic eye disease. A patented dementia-risk module —pairing a five-minute blood test with AI pattern recognition—is now in validation, while cardiovascular-risk analytics are advancing through pilot studies across Latin America. Because every new use case plugs into the same software backbone, Avant looks more like a scalable platform than a single-product company. On the financial side, the planned merger would fold all outstanding Ainnova shares into Avant's public float, avoiding cash dilution and fully aligning the combined team's incentives. Management says any future fund-raising would be aimed at three priorities: completing the automated camera, widening pharmacy deployments, and supporting U.S. regulatory milestones. Taken together, the pharmacy roll-out, planned Ainnova acquisition, and imminent camera launch signal a turning point for Avant. What began as an AI incubator is fast becoming a full-stack diagnostics company, complete with proprietary hardware, an expanding library of predictive algorithms, and retail-level distribution partners. If execution matches vision, Vision AI could cut referral delays, open earlier treatment windows, and give resource-strained health systems specialist-grade insight at primary-care prices—turning headline-grabbing tech into tangible patient benefits. NVIDIA Corporation (NASDAQ: NVDA) and Novo Nordisk A/S (NYSE: NVO) are joining forces to advance drug discovery using AI models trained on the NVIDIA DGX Cloud platform. The partnership is supported by Denmark's DCAI supercomputing center and aims to improve early-stage research for identifying drug targets and molecules. 'AI is essential for every industry, and there's no other field that will benefit more from acceleration than drug discovery,' said Rory Kelleher, senior director of business development for life sciences at NVIDIA. 'Working with Novo Nordisk, we're advancing critical R&D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development.' Novo Nordisk will adopt NVIDIA's BioNeMo platform to build customized generative AI tools using its proprietary biological data. 'By coupling NVIDIA's accelerated computing platform and expertise with Novo's deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,' said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk. 'Gefion will allow us to run experiments at an unprecedented scale.' DCAI views this collaboration as a model for how public supercomputing resources can unlock innovation in life sciences. For investors, the alliance highlights a rising trend of AI infrastructure enabling breakthroughs in biopharma. Alphabet, Inc. (NASDAQ: GOOG, GOOGL) subsidiary Google, through its DeepMind division, has introduced Med-Gemma, a new generative AI model optimized for healthcare developers building diagnostic and imaging apps. The tool aims to streamline early-stage development by offering pretrained models trained on expansive medical imaging datasets. Med-Gemma joins other Google health-focused initiatives like Med-PaLM 2 and AMIE, signaling a coordinated strategy toward AI-native clinical applications. The company continues to expand its AI footprint across healthcare with open-access tools designed to catalyze innovation at scale. Microsoft Corporation (NASDAQ: MSFT) is advancing healthcare AI innovation through strategic initiatives presented at HLTH Europe 2025, emphasizing breakthroughs in diagnostics and precision medicine via collaborations like its Mayo Clinic partnership. A central feature was Dragon Copilot, a generative AI tool designed to streamline documentation and enhance clinician-patient engagement across Europe. Microsoft also addressed growing global health disparities by promoting equitable, inclusive solutions rooted in responsible AI practices. These efforts reflect Microsoft's goal of enabling healthier outcomes for patients and providers worldwide. Source: CONTACT: cs@ (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Media Corp. ('BAY') BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it's respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
12 hours ago
- Business
- Cision Canada
AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape Français English
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /CNW/ -- Equity Insider News Commentary – Amid the wave of new AI-powered innovations in healthcare, so far ambient scribes have emerged as the breakout use case. As the range of AI uses for the healthcare sector continues to grow, experts are analyzing the potential ROI on their implementation, and how much they'll benefit early adopters. Healthcare leaders are already seeing improvements, such as slashed clinician workloads from voice AI, and the adoption of AI agents to increase efficiency and smarter care delivery. For investors looking for remaining early-mover advantages, there have been several publicly-traded companies with recent developments worthy of capturing their attention, including Avant Technologies, Inc. (OTCQB: AVAI), Spectral AI, Inc. (NASDAQ: MDAI), Palantir Technologies (NADSAQ: PLTR), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and CeriBell, Inc. (NASDAQ: CBLL). Investor interest in private companies is surging, as venture capital continues to pour into the AI-in-healthcare space. In Q1 alone, AI firms accounted for more than half of all digital health funding. Recent raises include $45 million for Ellipsis Health and $28 million for Autonomize AI, both targeting next-gen clinical intelligence. From diagnostics to drug discovery, the pace of innovation is accelerating — and many of these rollouts are now catching the attention of retail investors. One example is the rollout of AI-powered screenings for diabetic retinopathy now underway across Costa Rica, Nicaragua, and Panama. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. The fast, non-invasive test detects early retinal changes—often before symptoms appear—and delivers secure results within minutes. By embedding the service in retail pharmacies and preparing for a parallel launch in Mexico, the partners are bringing care closer to patients while generating real-world data to support broader commercialization. "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient." The rollout also gives Avant a timely proof point as it moves to consolidate Vision AI under one roof. Earlier this month, the company signed a non-binding letter of intent to acquire 100% of Ainnova Tech —bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Management sees the unified cap table as a potential draw for both investors and strategic partners. While the legal teams work through due diligence, engineers are finalizing a low-cost, automated retinal camera built to work seamlessly with the Vision AI platform. Legacy fundus cameras can run into the tens of thousands and typically require skilled operators. Avant's prototype is fully automated, cloud-connected, and designed for a fraction of the cost. If performance holds up to internal testing, the system could enable large-scale diabetic screenings in clinics and low-resource settings—without the need for additional specialist staff. Vision AI is also expanding beyond diabetic eye disease. A patented dementia-risk module —pairing a five-minute blood test with AI pattern recognition—is now in validation, while cardiovascular-risk analytics are advancing through pilot studies across Latin America. Because every new use case plugs into the same software backbone, Avant looks more like a scalable platform than a single-product company. On the financial side, the planned merger would fold all outstanding Ainnova shares into Avant's public float, avoiding cash dilution and fully aligning the combined team's incentives. Management says any future fund-raising would be aimed at three priorities: completing the automated camera, widening pharmacy deployments, and supporting U.S. regulatory milestones. Taken together, the pharmacy roll-out, planned Ainnova acquisition, and imminent camera launch signal a turning point for Avant. What began as an AI incubator is fast becoming a full-stack diagnostics company, complete with proprietary hardware, an expanding library of predictive algorithms, and retail-level distribution partners. If execution matches vision, Vision AI could cut referral delays, open earlier treatment windows, and give resource-strained health systems specialist-grade insight at primary-care prices—turning headline-grabbing tech into tangible patient benefits. Spectral AI, Inc. (NASDAQ: MDAI) continues to advance its DeepView® System, an AI-powered wound imaging platform designed to assess burn healing potential without invasive biopsies. The company's technology was recently spotlighted at the British Burn Association Conference, where new clinical data from UK hospitals showed DeepView® improved detection rates from 61% to 89%. "UK investigators shared valuable advancements with DeepView during the BBA meeting," said Dr. Jeffrey Carter, M.D., Louisiana State University Health Science Center. "Their early clinical experience demonstrated promising sensitivity and specificity results, along with a positive patient experience and a comprehensive evaluation of TBSA (Total Body Surface Area) calculation methods." The system aims to accelerate triage decisions and reduce treatment errors in both civilian and military burn care. Palantir Technologies (NADSAQ: PLTR) has entered into a strategic partnership with TeleTracking Technologies to deliver AI-powered operational insights to hospitals and health systems. The collaboration combines TeleTracking's Operations IQ platform with Palantir's Foundry and AIP, offering real-time visibility into staffing, capacity, and patient flow. "This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of-where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care," said Alex Karp, CEO at Palantir. According to both companies, the platform will unlock real-time visibility across health systems while easing the load on overburdened staff. Executives describe it as a foundational shift toward AI-native operations in healthcare. GE HealthCare Technologies Inc. (NASDAQ: GEHC) has partnered with Stanford Medicine to advance total-body PET/CT technology that incorporates AI into every stage of the imaging process. The system delivers high-resolution, full-body scans in a fraction of the time, while reducing radiation dose for patients. "Our total body PET/CT technology represents the next chapter in our enduring commitment to advancing medical imaging," said Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. "We're proud to collaborate with world-class institutions to explore new clinical frontiers in oncology and beyond. Together with our MIM software solutions, we're designing flexible, AI-enhanced tools that not only aim to enhance diagnostic confidence and operational efficiency but also help clinicians deliver more precise, personalized care that can truly improve patient outcomes." Key to the innovation is a deep-learning reconstruction engine that enhances detail and enables exploratory insights across oncology, cardiology, and neurology. GE HealthCare sees the platform as a foundation for identifying novel biomarkers, guiding treatment, and supporting large-scale clinical research. CeriBell, Inc. (NASDAQ: CBLL) is gaining momentum with its Rapid Response EEG system, which uses artificial intelligence to detect non-convulsive seizures in critical care settings. The company reported over 54,000 patients monitored in Q1 2025 alone, with 70% of seizures identified outside neurology departments—highlighting its utility in high-pressure environments. "We are pleased with our strong start to the year as we further expanded our account base while benefiting from accelerated adoption of the Ceribell system," said co-founder and CEO Jane Chao, Ph.D. "We also look forward to offering our pediatric Clarity algorithm to customers while continuing to invest in our product development pipeline with the goal of ultimately making EEG a new vital sign." With multiple AI modules, including seizure triage and brain function trending, Ceribell is becoming a key player in real-time neurological diagnostics. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
3 days ago
- Business
- Cision Canada
AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers
VANCOUVER, BC, June 17, 2025 /CNW/ -- Venture Capital continues to flow in bunches into the AI in healthcare sector, with AI companies capturing more than half of digital health funding in Q1. Investors are seeking novel opportunities that tap into this space, with private companies such as Ellipsis Health and Autonomize AI recently receiving $45M and $28M respectively for their innovations. For other investors seeking opportunities among publicly traded companies, there's been plenty of development to follow from innovators, including from Avant Technologies, Inc. (OTCQB: AVAI), IQVIA Holdings Inc. (NYSE: IQV), SoundHound AI, Inc. (NASDAQ: SOUN), RadNet, Inc. (NASDAQ: RDNT), and The Cigna Group (NYSE: CI). According to McKinsey's Global Institute, generative AI isn't just a buzzword — it could deliver between $60 and $110 billion in annual value just within pharma and medical products. Meanwhile, Statista now expects the broader AI healthcare market to explode from $11 billion today to a staggering $188 billion by 2030, reflecting a major shift in how technology is expected to transform patient care, diagnostics, and operational efficiency. For example, screenings for diabetic retinopathy are now live across Costa Rica, Nicaragua, and Panama after Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech began rolling out free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. The quick, non-invasive test looks for early retinal changes that often appear before symptoms, then delivers secure results in minutes. By placing the service in retail pharmacies—and preparing a parallel launch in Mexico—the partners are moving care closer to patients while collecting real-world evidence that can guide wider commercialization. "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient." The live-patient campaign gives Avant a timely proof point as it works to bring Vision AI under one roof. Earlier this month the company signed a non-binding letter of intent to acquire 100% of Ainnova, unifying leadership, intellectual property, and data ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would eliminate the current holding-company structure and streamline everything from regulatory filings to revenue recognition. Management believes the simplified cap table will resonate with investors and prospective partners alike. While the corporate lawyers handle due diligence, engineers are putting final touches on a low-cost, automated retinal camera designed to pair seamlessly with Vision AI. Traditional fundus cameras can cost tens of thousands of dollars and require skilled technicians. Avant's prototype is hands-free, feeds images directly into the cloud platform, and is expected to ship at a fraction of legacy pricing. If performance data match internal tests, primary-care clinics and resource-constrained health systems could screen large diabetic populations without adding specialist staff. Vision AI itself is also widening its clinical scope. A patented dementia-risk module —combining a five-minute blood assay with AI pattern recognition—remains in validation, while cardiovascular-risk analytics are progressing through pilot studies in Latin America. Each new indication plugs into the same software backbone, positioning Avant as a platform rather than a single-product story. Financially, the merger would roll all outstanding Ainnova equity into the publicly traded company, avoiding cash dilution and aligning incentives for the combined team. Leadership has signaled that post-deal capital raises, if needed, would be targeted toward finishing the camera, scaling pharmacy deployments, and supporting U.S. regulatory work. Taken together, the live pharmacy screenings, pending acquisition, and upcoming device launch mark a pivotal stretch for Avant. The company is evolving from an AI incubator into a full-stack diagnostics firm with proprietary hardware, a growing menu of predictive algorithms, and on-the-ground distribution partners. If the strategy holds, Vision AI could shorten referral times, open earlier treatment windows, and give emerging-market providers affordable access to specialist-level insights—translating technology headlines into measurable patient impact. IQVIA Holdings Inc. (NYSE: IQV) has launched a new suite of AI agents tailored for the life sciences and healthcare sectors. "This is a pivotal opportunity to deliver the precise, efficient workflows and insights required by the modern life sciences industry," said Bhavik Patel, President of Commercial Solutions of IQVIA. "Our collaboration with NVIDIA helps us realize our vision to power smarter healthcare for everyone, everywhere." Built using NVIDIA's NIM Agent Blueprints and NeMo platforms, these agentic tools aim to accelerate research, streamline workflows, and improve clinical and commercial decision-making. The rollout marks a major step in applying domain-specific AI to real-world pharmaceutical challenges, from target identification to HCP engagement. SoundHound AI, Inc. (NASDAQ: SOUN) and Allina Health have launched"Alli," a conversational AI agent designed to improve the patient experience by automating key access points in the healthcare system. "Long wait times and administrative complexity can be a huge source of stress for patients," said Michael Anderson, Executive Vice President of Enterprise AI of SoundHound AI. "We are proud to partner with Allina Health on this important digital transformation. The organization is taking a forward-thinking approach by integrating AI to support patients with immediate, personalized assistance." Deployed inside Allina Health's Customer Experience Center, Alli connects directly with electronic medical records to authenticate callers and manage appointments. With 80% of calls now answered in under 45 seconds, the system has helped reduce wait times while freeing up staff for more complex patient needs. RadNet, Inc. (NASDAQ: RDNT) has acquired See-Mode Technologies, a company specializing in AI-powered ultrasound tools for thyroid and breast diagnostics. "Early deployment of See-Mode's FDA -approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time," said Dr. Howard Berger, President and Chief Executive Officer of RadNet. "The increase in capacity should improve our ability to drive better access and more revenue through RadNet's existing centers." The integration is expected to enhance operational capacity across RadNet's imaging centers and add value to its DeepHealth platform. With existing reimbursement pathways and a high annual volume of ultrasound exams, the acquisition is positioned to create new revenue opportunities and clinical efficiencies. Cigna Healthcare, a division of The Cigna Group (NYSE: CI), has rolled out a suite of AI-powered tools through its myCigna member portal to simplify key insurance tasks like finding care, checking benefits, and tracking costs. "Everyday moments in health care need to be easier," said Katya Andresen, Chief Digital and Analytics Officer of The Cigna Group. "These enhancements are a significant step in our journey to transform the experience and put customers at the heart of it." These enhancements include an AI virtual assistant, real-time cost tracking, personalized provider matching, and automated claim support. Early results show high user engagement and improved customer satisfaction, reinforcing Cigna's goal of making health coverage more intuitive and accessible. Source: need-to-know/ DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
4 days ago
- Health
- Cision Canada
Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies
LAS VEGAS, June 17, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that screenings for diabetic retinopathy begin this week in collaboration with Grupo Dökka and its leading pharmacy subsidiaries, Fischel Pharmacies and La Bomba Pharmacies located in Central America. Both Fischel and La Bomba Pharmacies have asked their diabetic customers to schedule a free screening as part of a collaborative program where Ainnova will use its cutting-edge AI platform, Vision AI, to help identify changes in the retina using a quick and non-invasive scan of the patient's retina. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., a joint venture company created by both Avant and Ainnova, said of the benefits for the collaboration, "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment—connecting every step of the journey. We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive: the well-being of the diabetic patient. Projects like this allow us to validate the model across diverse populations and sectors as part of our strategy to reach the market in a smarter, more efficient way—where the biggest winners are the patients." Diabetic retinopathy is one of the main causes of vision loss in people with diabetes. Although, in its early stages, it may not present symptoms, it can be detected with a simple and quick screening. The screenings are important for: Prevention: Screenings will detect changes in the retina before they affect vision. Speed: Each screening takes only a few minutes. Peace of Mind: Patients will receive the results of the screening in a secure and timely manner. Grupo Dökka, which operates in Costa Rica, Nicaragua, and Panama with expansion expected into other Central American countries, has created numerous innovative platforms, including storage and distribution, pharmacies, and marketing and sales, that provide access to comprehensive health and well-being solutions for all people. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Globe and Mail
10-06-2025
- Business
- Globe and Mail
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /CNW/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL), Omada Health, Inc. (NASDAQ: OMDA), and Inc. (NASDAQ: AMZN).
